09-Nov-2016 By Dan Stanton
Increasing regulatory burdens are increasing costs and will create fewer, bigger, and better players in the CDMO space, according to Catalent’s CEO.
17-Aug-2015 By Fiona BARRY
An SEC filing reveals Merck has cut 29,160 jobs in five years, and over 2,500 more may be on the way.
24-Jul-2015 By Fiona BARRY
AmerisourceBergen has reported a good third quarter driven by an acquisition and a JV, but says stunted generic prices will slow income in 2016.
11-Nov-2014 By Zachary Brennan
Power interruptions and remediation work at AMRI’s Albuquerque, New Mexico facility, as well as unexpected delays to API shipments have driven down the company’s Q3 profits.
30-Oct-2013 By Gareth Macdonald
API, drug intermediates and formulations firm Granules India ended the second quarter of fiscal 2013 with higher revenue and profit thanks to gains made by all three of its units.
13-Jun-2013 By Zachary Brennan
Canadian CMO Patheon’s second quarter revenues increased almost 40 percent as the company’s commercial manufacturing services revenues saw a similarly high rise over the same period from last year.
31-Jul-2012 By Gareth Macdonald
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
05-Jun-2012 By Nick Taylor
Cetero Research posted a $3.1m (€2.5m) net loss in April as FDA rework expenses and reorganisation costs dragged on earnings.
24-Jan-2012 By Gareth Macdonald
Granules India says Big Pharma demand for highly efficient manufacturing in era of patent loss helped it gain market share in Q3 fiscal 2012.
20-Dec-2011 By Nick Taylor
Patheon posted a fourth quarter operating loss as costs related to restructuring offset an uptick in revenues.
Catalent up on ODT and clinical units’ performance
Catalent Pharma Solutions says gains made by its oral delivery tech business and clinical segment offset falling demand for packaging and sterile services in the first quarter of fiscal 2012.
Operating profits drop for Parexel thanks to restructuring costs
10-Aug-2011 By Natalie Morrison
Restructuring costs for Parexel have caused a dramatic drop in GAAP operating income, reveal the company’s Q4 results.
Alkermes' loss deepens in FY 2011 but firm upbeat on revs and EDT plans
19-May-2011 By Gareth Macdonald
Alkermes saw losses increase in fiscal 2011 but has issued an upbeat outlook on higher revenues, portfolio expansion and impending acquisition of Elan Drug Technologies (EDT).
Jubilant plans expansions, new plants to build in Q4 growth
11-May-2011 By Nick Taylor
Jubilant Life Sciences is to build an intermediate plant and expand production to continue double-digit growth seen in the fourth quarter.
Parexel cuts guidance & Phase I capacity after weak results
03-May-2011 By Nick Taylor
Parexel has slashed its guidance and is cutting early phase capacity after weak results, but hiring in other areas is accelerating.
ShangPharma revs up in Q4, but margins narrow
21-Mar-2011 By Gareth Macdonald
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
Early end to cephalosporin contract helps Patheon in Q1 fiscal 2011
15-Mar-2011 By Gareth Macdonald
A customer decision to halt development of an antibiotic and end a manufacturing contract early helped Patheon to an improved set results for the first quarter of fiscal 2011.
Outsourcing-Pharma rounds-up eClinical financial results
17-Nov-2010 By Alexandria Pešić
Outsourcing-Pharma reviews the latest financial reports from the eClinical sector with news from Datatrak International, Medidata Solutions and Perceptive Informatics.
Parexel’s profit rises in Q1, but FY 2011 may look bleaker
03-Nov-2010 By Alexandria Pešić
Cost cutting measures helped Parexel to one of its most profitable quarters after taking lower-than-expected revenues on project delays and cancellations.
BASi posts Q3 operating profit despite lower revenues
16-Aug-2010 By Nick Taylor
Bioanalytical Systems, Inc (BASi) posted an operating profit in the third quarter, overturning a loss 12 months ago, as lower expenses offset a slight dip in revenue.
Parexel grows revenue, op income in Q4 & full fiscal year
10-Aug-2010 By Nick Taylor
Parexel recorded growth in the fourth quarter, contributing to a 10 per cent increase in full year GAAP operating income and an improved backlog.
Chaotic discovery market hits PBI in Q3
17-May-2010 By Gareth Macdonald
Pacific Biomarkers (PBI) says “chaotic” drug discovery environment will continue for the rest of fiscal 2010 and cuts revenue forecast as expected recovery fails to materialise.
Wuxi income up in ’09, plans investments this year
09-Mar-2010 By Nick Taylor
WuXi PharmaTech posted an operating profit of $52m (€38m) in 2009 and is optimistic about 2010, when it will make investments in laboratory services and large-scale manufacturing to drive growth in coming years.
H1N1 components drive growth at West in Q4
22-Feb-2010 By Staff reporter
West Pharmaceutical Services reported strong fourth quarter results, underpinned by demand for H1N1 components, but still posted a dip in operating income for its 2009 financial year.
Lonza hit by lower demand last year; cuts capex in 2010
28-Jan-2010 By Gareth Macdonald
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Phase Forward plans bright 2010
02-Nov-2009 By Nick Taylor
In Q3 Phase Forward’s revenues from CROs grew by 44 per cent year-on-year and it predicts a bright 2010, as a backlog of delayed trials are started and big pharma attempts to cut IT costs.
Finished dosage growth helps Granules’ Q2
27-Oct-2009 By Nick Taylor
Increased focus on international markets, soaring demand for finished dosage forms and improved capacity usage helped India-based CMO Granules posting record revenues.
Dishman targets US & Japan in international expansion
14-Sep-2009 By Nick Taylor
Dishman is pushing ahead with its international expansion, increasing efforts to win contracts in the US and Japan and nearing completion of a facility Shanghai, China, which is the first it has built outside of India.
Medidata turns loss to profit in Q2
17-Aug-2009 By Nick Taylor
Medidata has followed its successful IPO by posting an operating profit in Q2, having made a loss last year, and giving a positive outlook for the rest of the year.
Accounting errors impact on Parexel in 09
13-Aug-2009 By Nick Taylor
Accounting errors related to the purchase of ClinPhone reduced Parexel’s operating income by $15.9m (€11.2m) in fiscal 2009 and the impact of these charges will continue into the next year.
China lab services shine for WuXi in Q2
12-Aug-2009 By Nick Taylor
Wuxi PharmaTech’s China-based laboratory services grew by 23 per cent in Q2, outstripping expectations and resulting in the company revising its guidance for the business segment.
Synthetech posts 220% rise in Q1 op income
The declining cost of raw materials helped Synthetech post a 220 per cent increase in operating income in the first quarter of its fiscal year, despite its revenues dropping.
Packaging up at AmerisourceBergen in Q3
04-Aug-2009 By Nick Taylor
AmerisourceBergen’s contract packaging business believes the outlook for the sector is improving after it posted an 11 per cent rise in operating income in Q3.
Phase Forward's income drops in Q2
28-Jul-2009 By Nick Taylor
Phase Forward’s GAAP net income fell by 41 per cent in Q2 despite an increase in revenues, as rising operating costs hit the company.
Chiltern posts positive annual results with 44% rise in revenue
15-Jul-2009 By Antoine Clarke
UK CRO Chiltern International announced positive financial results for the year ending March 2009, possibly suggesting a bounce for a sector that has been hit by project cancellations.
WuXi operating income down 25% in Q1
18-May-2009 By Nick Taylor
WuXi PharmaTech’s operating income fell by 25 per cent in Q1, in part because of an 81 per cent drop in revenues from manufacturing, but the company reconfirmed its 2009 financial guidance.
IMA’s 2009 on track but challenges may lie ahead
17-Feb-2009 By Gareth Macdonald
IMA chief financial officer Sergio Marzo says that although demand for its machines has been strong so far this year, the number of orders it receives in the second quarter will provide a better reflection of the pharmaceutical industry’s position.
Poor API sales send Perrigo stock tumbling
04-Feb-2009 By Nick Taylor
Falling API sales and “an unprecedented negative economic environment” have forced Perrigo to cut its fiscal 2009 profit forecast and sent stock plummeting by 20 per cent.
Peregrine unit Avid sees revenues decline in Q2
23-Dec-2008 By Phil Taylor
US drugmaker and contract manufacturer Peregrine narrowed its losses in the second fiscal quarter ending October 31, as a result of cost-cutting measures.
MDS Pharma Services under pressure in Q4
22-Dec-2008 By Phil Taylor
Canadian contract services company MDS Pharma Services reported disappointing results in its fiscal fourth quarter, with revenues dropping 9 per cent to $112m.
Encorium delays financial results
24-Nov-2008 By Phil Taylor
Clinical research organisation Encorium has postponed the release of its third quarter results but said it still expects the figures to be in line with its most up-to-date guidance.
Rough quarter for Ampac Fine Chemicals
07-Aug-2008 By Nick Taylor
Ampac Fine Chemicals has posted disappointing results for the third quarter of its fiscal year, which saw operating income slump from $5m to $0.6m.
CRAMS sector key to Anu's future
08-Jul-2008 By Gareth Macdonald
Indian contract drugmaker Anu's Laboratories will focus its efforts
on expanding its presence in the country's booming contract
research and manufacturing (CRAMS) market, according to managing
director Hari Babu.
PharmaNet sees red over contract cancellations; looks to cut costs
13-May-2008 By Kirsty Barnes
PharmaNet has found itself back in the red again alter a
disappointing first quarter of 2008 and has announced a series of
cost-cutting measures in response.
Generic drag cant hold back Siegfried's API momentum
20-Mar-2008 By Staff reporter
Switzerland's Siegfried Holding says that a significant jump in
2007 net profit, up 54 per cent to CHF 49.7m ($50m), vindicates its
decision to refocus on the active pharmaceutical ingredients and
Ferro's pharma business falters in Q4, 2007
05-Mar-2008 By Pete Mansell
There were distinct signs of faltering progress in the
pharmaceutical business of US-based performance materials supplier
Ferro Corporation during the fourth quarter and year ended 31
IMA positive about 2008 prospects despite slight 4th-qtr decline
18-Feb-2008 By staff reporter
Fourth quarter operating profit at Italian packaging automation
firm IMA SpA fell some 8.5 per cent to €27m, while its revenue for
the period declined 4.2 per cent to €147m, although pharma sales,
buoyed by acquisitions, kept its...
Covance reports financial gains
05-Feb-2008 By staff reporter
Covance reported financial gains for its fourth quarter of 2007,
along with a 20.6 per cent growth in backlog to $2.7bn.
Icon improves its position, Kendle slips again
06-Nov-2007 By Kirsty Barnes
Icon has improved its financial position significantly during its
third quarter, while its smaller US rival Kendle saw its profit
slip again, weighed down by charges from a 2006 acquisition.
Parexel profits perky in Q1
01-Nov-2007 By Kirsty Barnes
Parexel has seen its profits remain perky during its first
financial quarter of 2008.